Morphotek, a subsidiary of Eisai Inc., announced today that the U.S. Food and Drug Administration accepted an Investigational New Drug (IND) Application for MORAb-202, an antibody-drug conjugate (ADC), to treat solid tumors that express folate receptor alpha (FRA).     A Phase 1 dose-escalation study will be conducted in the U.S. to evaluate the safety and preliminary efficacy of MORAb-202 in patients with solid tumors that express FRA.  The solid tumors to be studied include advanced or...